Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer

Frontiers in Immunology - Switzerland
doi 10.3389/fimmu.2018.00283
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells as an “Off-The-Shelf Immunotherapy” for Improvement in Cancer Treatment

Frontiers in Immunology
AllergyImmunology
2017English

Chimeric Antigen Receptor CAR NK Cells Emerging Immunotherapy for the Treatment of Cancer

2019English

Induced Pluripotent Stem (iPS) Cell–derived, Chimeric Antigen Receptor (CAR)-expressing T Cells for Immunotherapy

Science-Business eXchange
2013English

Development of GPC3-specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2018English

An Introduction to Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Human Cancer

American Journal of Hematology
Hematology
2019English

Targeting Natural Killer Cells for Tumor Immunotherapy

Frontiers in Immunology
AllergyImmunology
2020English

Targeting Cancer Stem Cells With Natural Killer Cell Immunotherapy

Expert Opinion on Biological Therapy
Drug DiscoveryClinical BiochemistryPharmacology
2016English

Chimeric NKG2D Receptor-Bearing T Cells as Immunotherapy for Ovarian Cancer

Cancer Research
Cancer ResearchOncology
2007English

Chimeric Antigen Receptor T-Cells

Cancer Journal
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy